Journal
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
Volume 32, Issue 2, Pages 253-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.idc.2018.02.002
Keywords
Hepatitis C; Comorbidities; Cirrhosis; Sustained viral response; Direct-acting antiviral; Mortality; Real-world cohort
Categories
Funding
- CHeCS from the Centers for Disease Control and Prevention [1U18PS005154]
- Gilead Sciences
- CDC Foundation [MOA-481-09, MOA-481-15]
- AbbVie
- Genentech
- Janssen Pharmaceuticals, Inc
- Vertex Pharmaceuticals
- Bristol-Myers Squibb
Ask authors/readers for more resources
Chronic Hepatitis Cohort Study (CHeCS) publications using data from real world patients with hepatitis C virus (HCV) have described demographic disparities in access to care; rates of advanced liver disease, morbidity, and mortality (2.5%-3.5% per year during 2006-10, although only 19% of all CHeCS decedents, and just 30% of those with deaths attributed to liver disease, had HCV listed on death certificate); substantial comorbidities, such as diabetes, advanced liver fibrosis (29% prevalence), renal disease, and depression, and partial reversal of all these with successful antiviral therapy; patient risk behaviors; and use of noninvasive markers to assess liver disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available